Certest嗜肺军团菌单抗（克隆LN14） 返回列表页

西班牙Certest嗜肺军团菌单抗(克隆LN14)

广州健仑生物科技有限公司

广州健仑长期供应各种生物原料，主要代理品牌：西班牙Certest。

主要产品包括各种生物单克隆抗原抗体、重组蛋白。

西班牙Certest嗜肺军团菌单抗(克隆LN14)

我司还提供其它进口或国产试剂盒：登革热、疟疾、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。

欢迎咨询

欢迎咨询2042552662

【产品介绍】

西班牙Certest嗜肺军团菌单抗(克隆LN14)

目前，研究人员正在进行毒理学、细胞移植、预临床研究和临床研究之前的概念验证等研究。他们表示，研究让他们朝着利用干细胞移植治疗人类疾病又迈近了一步。
人体的另一个谜题已经被科学家解开了，科学家已经确定了一个在人类发育工作中*的分子马达。他们还正确的指出，与该马达相关的基因突变为什么会引发各种各样的人类疾病。
英国布里斯托尔大学的研究人员已经确定了人类版本的分子马达组成，它被称为“胞质动力蛋白-2”，这对于正常的人类发育有着至关重要的作用。动力蛋白2指引分子进入纤毛以及控制其沿着纤毛运动。
纤毛是一种细长突起，几乎充当了所有人体细胞的触须，它们在传感信号指导细胞功能中具有很重要的作用。已知，纤毛功能失调会引发长期瘫痪和有时甚至危及生命的遗传病。这会对多个系统产生影响，导致失明，耳聋，慢性呼吸道感染，肾疾病，心脏疾病，抗原抗体，肥胖和糖尿病。
这些人类疾病统称为ciliopathies，其中许多这种疾病，包括年轻综合征(Jeune Syndrome)，都与儿童的发育有关。在英国，每10万个婴儿中就有一个在出生时患有年轻综合征——这是一种罕见的遗传疾病，会影响孩子的软骨和骨骼发育。
这项新的研究是由医学研究委员会资助，并且发表于2014年9月9日的《Journal of Cell science》杂志上，*精确的解释人类胞质动力蛋白-2马达是如何工作的。这项新的成果可能有助于诊断，并且科学家希望他们能够改变缺陷马达的功能，有益于治疗。
来自布里斯托尔大学的生物化学学院的戴维·斯蒂芬斯教授了这项研究。他说：“这个马达新组分的发现，给我们提供了一个很好地机会，去了解缺乏动力蛋白-2是如何引发疾病的。”
在简单的模型生物体(如绿藻)上完成工作，研究还表明，与年轻综合征相关的两个基因(WDR34和WDR60)是人类版本中这种马达的必要组成部分。
形成一个功能性动力蛋白-2马达需要这两个基因编码的蛋白质，这就解释了为什么任一个基因发生突变都会引发ciliopathy。这项工作还确定了动力蛋白-2的新组分(TCTEX1D2)，提供一个候选基因，其突变或可导致年轻综合征。

西班牙Certest嗜肺军团菌单抗(克隆LN14)

想了解更多的产品及服务请扫描下方二维码：

【公司名称】 广州健仑生物科技有限公司
【市场部】    杨永汉

【】 
【腾讯  】 2042552662
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-103室

Currently, researchers are conducting toxicology, cell transplantation, pre-clinical studies and proof-of-concept studies prior to clinical studies. They said the latest research has taken them one step closer to using stem cell transplantation to treat human disease.
Another mystery of the human body has been solved by scientists, who have identified a molecular motor that is indispensable in the work of human development. They also rightly pointed out why genetic mutations associated with the motor can trigger a wide range of human diseases.
Researchers at the University of Bristol in the United Kingdom have identified a human version of the molecular motor composition called "cytoplasmic dynein-2," which plays a crucial role in normal human development. Motokin 2 directs molecules into the cilia and controls their movement along the cilia.
Cilia is an elongated protrusion that acts almost as a whisker of all human cells and plays an important role in sensing signaling functions of cells. It is known that cilia dysfunction can cause long-term paralysis and sometimes life-threatening genetic diseases. This can affect multiple systems, resulting in blindness, deafness, chronic respiratory infections, kidney disease, heart disease, antigen-antibody, obesity and diabetes.
These human diseases are collectively referred to as ciliopathies, and many of these diseases, including the Jeune Syndrome, are related to children's development. In the UK, one out of every 100,000 infants is born with a young syndrome - a rare genetic disorder that affects the child's cartilage and bone development.
This new study, funded by the Medical Research Council and published in the September 9, 2014 issue of the Journal of Cell Sciences, for the first time accuray explains how the human cytoplasmic dynein-2 motor works. The new results may help diagnose, and scientists hope they will be able to change the function of the defective motor, beneficial treatment.
Professor David Stephens from the University of Bristol's School of Biochemistry led the study. "The discovery of new components in this motor provides us with a good opportunity to understand how the lack of dynamin-2 can trigger disease," he said.
Working on a simple model organism, such as green algae, studies have also shown that two genes associated with young syndromes (WDR34 and WDR60) are essential components of this motor in the human version.
The formation of a functional dynein-2 motor requires proteins encoded by both genes, which explains why mutations in either gene can trigger ciliopathy. This work also identified a new component of dynein-2 (TCTEX1D2), which provides a candidate gene whose mutation may lead to young syndrome.